Sativex® successfully launched in UK, Germany, Spain and Denmark - strong initial uptake in key German market recently reported by marketing partner, Almirall
· Licence agreement signed with Novartis to commercialise Sativex in Australasia, Asia (excluding Japan/China), Middle East (excluding Israel) and Africa. $5m upfront payment received. Regulatory submission filed in Australia. · Sativex approved in Czech Republic and further approvals in Italy, Sweden, and Austria expected in the coming months. Launches in these countries expected in 2012 · Second European Mutual Recognition Procedure submission procedure now underway with aim to expand approvals to up to ten additional European countries in 2012 (see separate release today) · Expansion of facilities and staff to support sales growth and R&D activity
